Calton & Associates Inc. Sells 687 Shares of CVS Health Co. (NYSE:CVS)

Calton & Associates Inc. reduced its stake in shares of CVS Health Co. (NYSE:CVSGet Rating) by 13.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,375 shares of the pharmacy operator’s stock after selling 687 shares during the quarter. Calton & Associates Inc.’s holdings in CVS Health were worth $442,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Tudor Investment Corp Et Al bought a new position in shares of CVS Health during the third quarter valued at approximately $2,287,000. MFA Wealth Advisors LLC bought a new position in shares of CVS Health during the third quarter valued at approximately $105,000. Schonfeld Strategic Advisors LLC grew its stake in shares of CVS Health by 428.8% during the third quarter. Schonfeld Strategic Advisors LLC now owns 132,207 shares of the pharmacy operator’s stock valued at $11,219,000 after buying an additional 107,207 shares during the last quarter. Summit Trail Advisors LLC grew its stake in shares of CVS Health by 12.2% during the third quarter. Summit Trail Advisors LLC now owns 4,170 shares of the pharmacy operator’s stock valued at $354,000 after buying an additional 454 shares during the last quarter. Finally, Studio Investment Management LLC purchased a new stake in shares of CVS Health in the third quarter valued at approximately $2,950,000. 78.00% of the stock is currently owned by institutional investors.

A number of brokerages recently issued reports on CVS. Deutsche Bank Aktiengesellschaft boosted their price target on CVS Health from $110.00 to $113.00 in a report on Thursday, May 5th. Tigress Financial boosted their price target on CVS Health from $122.00 to $125.00 in a report on Thursday, April 7th. Loop Capital began coverage on CVS Health in a report on Thursday, June 16th. They issued a “buy” rating and a $120.00 price target for the company. Sanford C. Bernstein lowered CVS Health from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $122.00 to $112.00 in a report on Thursday, May 26th. Finally, StockNews.com started coverage on CVS Health in a report on Thursday, March 31st. They set a “strong-buy” rating for the company. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $116.05.

Shares of CVS stock opened at $91.29 on Thursday. The business’s fifty day simple moving average is $97.08 and its 200-day simple moving average is $101.42. The company has a market cap of $119.71 billion, a PE ratio of 15.16, a PEG ratio of 1.44 and a beta of 0.78. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.70. CVS Health Co. has a 12-month low of $79.33 and a 12-month high of $111.25.

CVS Health (NYSE:CVSGet Rating) last issued its quarterly earnings results on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.08. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. The business had revenue of $76.83 billion for the quarter, compared to the consensus estimate of $75.30 billion. During the same period in the prior year, the firm posted $2.04 earnings per share. The business’s quarterly revenue was up 11.2% on a year-over-year basis. On average, equities analysts forecast that CVS Health Co. will post 8.34 earnings per share for the current year.

In related news, EVP Prem S. Shah sold 16,954 shares of the company’s stock in a transaction on Friday, April 8th. The stock was sold at an average price of $105.00, for a total value of $1,780,170.00. Following the transaction, the executive vice president now directly owns 43,453 shares of the company’s stock, valued at approximately $4,562,565. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Daniel P. Finke sold 55,359 shares of the company’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $100.13, for a total value of $5,543,096.67. Following the completion of the transaction, the executive vice president now directly owns 3,098 shares in the company, valued at $310,202.74. The disclosure for this sale can be found here. Over the last three months, insiders sold 77,659 shares of company stock worth $7,882,993. 0.69% of the stock is owned by insiders.

About CVS Health (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Featured Articles

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.